Atezolizumab receives positive opinion for advanced urothelial cancer, NSCLC

medwireNews: Following a positive opinion by the European Medicines Agency (EMA), atezolizumab may soon be available for patients with locally advanced or metastatic urothelial carcinoma or non-small-cell lung cancer (NSCLC).

In the urothelial cancer setting, the anti-programmed cell death ligand 1 antibody is intended for patients who have progressed on platinum-based chemotherapy or are unable to receive cisplatin.

And NSCLC patients can receive atezolizumab monotherapy if they have progressed on prior chemotherapy and also on targeted therapy if they harbor EGFR activating mutations or ALK translocations.

Atezolizumab treatment is associated with a variety of side effects, including fatigue, decreased appetite, nausea, dyspnea and diarrhea, and also with immune-related toxicities, such as pneumonitis, hepatitis, and colitis.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

See also:

• ‘Encouraging’ results with post-progression atezolizumab in NSCLC